This category covers biotechnology and pharmaceutical companies developing iron chelation therapies for the treatment of Parkinson's disease (PD). Iron accumulation in the substantia nigra pars compacta is a well-established pathological feature of PD, contributing to oxidative stress, ferroptosis, and dopaminergic neuron death["1"][2][3]. Iron chelation therapy aims to reduce brain iron levels through administration of chelating agents that can cross the blood-brain barrier, potentially slowing or halting disease progression.
Unlike symptomatic treatments that address dopamine deficiency, iron chelation represents a disease-modifying approach that targets a fundamental pathological process. The FAIRPARK-II clinical trial demonstrated that the iron chelator deferiprone can significantly reduce brain iron levels and slow disease progression in early PD patients, providing proof-of-concept for this therapeutic strategy["1"][2].
Scientific Rationale
Iron Accumulation in Parkinson's Disease
The substantia nigra in PD patients shows selective iron accumulation that exceeds what is seen in normal aging:
Increased iron influx: Dysregulation of transferrin receptors and divalent metal transporter 1 (DMT1) leads to excessive iron entry into neurons
Impaired iron export: Ferroxidase activity is reduced, limiting the conversion of iron for export via ferroportin
Protein aggregation interactions: Alpha-synuclein can bind iron, potentially facilitating its accumulation
Microglial activation: Iron-laden microglia release iron into the surrounding tissue
Neuromelanin saturation: Neuromelanin, which normally buffers iron, becomes saturated[3]
Iron-Dependent Neurotoxicity
The accumulated iron contributes to neurodegeneration through several mechanisms:
Fenton Chemistry: Ferrous iron (Fe²⁺) reacts with hydrogen peroxide to generate hydroxyl radicals, causing oxidative damage to lipids, proteins, and DNA
Ferroptosis Induction: Iron is required for lipid peroxidation accumulation in ferroptosis, an iron-dependent form of regulated cell death
Mitochondrial Dysfunction: Iron overload impairs mitochondrial Complex I activity, reducing ATP production
Neuroinflammation: Iron-laden microglia adopt a more pro-inflammatory phenotype[3][4]
Clinical Proof-of-Concept
The FAIRPARK-II trial (NCT03242382) provided the first robust clinical evidence that iron chelation can modify PD progression:
Apopharma Inc. (Subsidiary of Chiesi Farmaceutici)
Focus: Iron chelation therapy for neurodegenerative diseases
Lead Candidate: Deferiprone (Ferriprox/Kelfer)
Indication: Parkinson's disease
Stage: Phase II completed, Phase III planning
Mechanism: Oral bidentate hydroxypyridone chelator that crosses the blood-brain barrier and reduces brain iron stores
Clinical Data: FAIRPARK-II trial demonstrated significant brain iron reduction in substantia nigra and putamen, with signal of reduced disease progression on MDS-UPDRS[1][2]
Key Advantages:
Only iron chelator with positive Phase II data in PD
Demonstrated brain iron reduction in human trials
Oral bioavailability vs. injectable alternatives
Related Page: [Apopharma Inc.](/companies/apopharma)
Related Therapeutic: [Iron Chelation Therapy for Parkinson's Disease](/therapeutics/iron-chelation-therapy-parkinsons-disease)
Novartis AG
Focus: Iron chelation therapy for neurodegenerative diseases
Lead Candidate: Deferasirox (Exjade/Jadenu)
Indication: Parkinson's disease (exploratory)
Stage: Phase I completed
Mechanism: Once-daily oral iron chelator with improved tolerability profile compared to deferoxamine
Clinical Data: Phase I trial (NCT02655315) in early PD demonstrated safety and tolerability, with trend toward reduced brain iron
Related Page: [Novartis](/companies/novartis)
Notes: Deferasirox is already approved for iron overload (thalassemia) and has a well-characterized safety profile
Roche
Focus: Iron chelation therapy legacy programs
Lead Candidate: Deferoxamine (Desferal)
Historical Context: Early PD studies in 1980s-1990s established proof that iron can be reduced in the brain, but limited BBB penetration and subcutaneous administration were barriers
Related Page: [Roche](/companies/roche)
Notes: While not actively pursuing PD, deferoxamine established the foundational concept that iron reduction in the brain is achievable
Preclinical/Discovery Stage Companies
Emerging Iron Chelation Programs
Several companies and academic groups are developing next-generation iron chelators with enhanced properties:
| Company | Candidate | Mechanism | Status | Notes | |---------|-----------|-----------|--------|-------| | VARX | VARX-002 | Brain-penetrant iron chelator | Discovery | Enhanced BBB penetration | | Various | CLO (clioquinol) | Metal-protein attenuation | Preclinical | Combined chelator and antioxidant | | Various | SBT-272 | Mitochondrial-targeted iron chelator | Preclinical | Targets mitochondrial iron overload |
Research Consortia and Academic Programs
University of Lille (France): Prof. David Devos, Dr. Caroline Moreau — FAIRPARK clinical program
European Parkinson's Study Group: Clinical trial network for iron chelation approaches
Various: Basic research on GPX4 biology, ACSL4 vulnerability, and ferroptosis in dopaminergic neurons
Pipeline Overview
| Company | Drug | Mechanism | Indication | Stage | |---------|------|-----------|-----------|-------| | Apopharma | Deferiprone | Iron chelation | PD | Phase II completed | | Novartis | Deferasirox | Iron chelation | PD | Phase I completed | | Roche | Deferoxamine | Iron chelation | PD (historical) | Phase I/II completed | | Various | VARX-002 | Brain-penetrant chelator | PD | Discovery | | Various | CLO | Chelator + antioxidant | PD | Preclinical | | Various | SBT-272 | Mito-targeted chelator | PD | Preclinical |
Therapeutic Approaches
First-Generation Chelators
Deferoxamine (Desferal)
Established proof that brain iron can be reduced
Requires subcutaneous or intravenous administration
Limited BBB penetration
Deferiprone (Ferriprox)
First oral chelator to show efficacy in PD
Demonstrated disease-modifying potential in FAIRPARK-II
Requires weekly CBC monitoring for neutropenia
Deferasirox (Exjade/Jadenu)
Once-daily oral dosing
Improved tolerability profile
Early-phase PD trials completed
Next-Generation Approaches
Enhanced BBB Penetration: New chelators with improved brain delivery
Mitochondrial Targeting: Chelators that specifically target mitochondrial iron overload